News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
718,020 Results
Type
Article (66383)
Company Profile (301)
Press Release (651336)
Section
Business (203848)
Career Advice (3020)
Deals (35975)
Drug Delivery (90)
Drug Development (84665)
Employer Resources (169)
FDA (16497)
Job Trends (15630)
News (350513)
Policy (34305)
Tag
Academia (2897)
Africa (1033)
Alliances (51120)
Alzheimer's disease (1231)
Approvals (16437)
Arizona (145)
Artificial intelligence (73)
Asia (42253)
Australia (7419)
Bankruptcy (320)
Best Places to Work (11780)
Biosimilars (64)
Biotechnology (199)
C2C Services and Suppliers (78309)
California (1415)
Canada (776)
Cancer (328)
Career advice (2550)
Cell therapy (112)
China (93)
Clinical research (65667)
Collaboration (100)
Colorado (61)
Connecticut (57)
COVID-19 (2678)
Cystic fibrosis (76)
Data (108)
Diabetes (66)
Diagnostics (6244)
Drug pricing (64)
Earnings (76334)
Employer resources (145)
Europe (97110)
Events (109571)
Executive appointments (85)
FDA (16638)
Florida (193)
Funding (83)
Gene therapy (81)
GLP-1 (566)
Government (4837)
Healthcare (19777)
Hotbed/Location (476180)
Idaho (61)
Illinois (261)
Indiana (133)
Infectious disease (2703)
Inflammatory bowel disease (98)
Interviews (572)
IPO (16390)
Job creations (3964)
Job search strategy (2153)
Kansas (92)
Layoffs (439)
Legal (8092)
Liver cancer (58)
Lung cancer (73)
Manufacturing (73)
Maryland (330)
Massachusetts (1220)
Medical device (13319)
Medtech (13322)
Mergers & acquisitions (19401)
Metabolic disorders (234)
Michigan (116)
Minnesota (196)
Neuroscience (1343)
New Jersey (391)
New York (461)
NextGen Class of 2024 (7111)
Non-profit (4928)
North Carolina (617)
Northern California (657)
Obesity (142)
Ohio (96)
Opinion (220)
Pennsylvania (479)
People (60021)
Pharmaceutical (67)
Phase I (20223)
Phase II (28767)
Phase III (21627)
Pipeline (81)
Podcasts (57)
Postmarket research (2992)
Preclinical (8916)
Rare diseases (116)
Real estate (6401)
Recruiting (67)
Regulatory (22277)
Research institute (2585)
Resumes & cover letters (463)
South America (1359)
Southern California (577)
Startups (3677)
Texas (179)
United States (7013)
Vaccines (512)
Washington State (223)
Weight loss (135)
Date
Today (48)
Last 7 days (319)
Last 30 days (2546)
Last 365 days (38654)
2024 (24615)
2023 (40792)
2022 (52014)
2021 (56898)
2020 (55828)
2019 (49372)
2018 (37457)
2017 (34325)
2016 (34343)
2015 (40071)
2014 (33759)
2013 (29884)
2012 (31388)
2011 (31240)
2010 (30150)
718,020 Results for "national institute of allergy and infectious diseases niaid".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Traverse Biotech Awarded Phase I SBIR Grant by the National Institute of Allergy and Infectious Diseases for Development of Innate Immune Stimulator
Traverse Biotech, Inc. has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH.
May 1, 2024
·
1 min read
BioCapital
ReAlta Life Sciences Announces New Research Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate RLS-0071 as a Medical Countermeasure for Acute Radiation Syndrome
ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”) today announces that the company will be utilizing the preclinical services program offered by the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate RLS-0071 as a medical countermeasure for Acute Radiation Syndrome (ARS).
March 28, 2024
·
3 min read
Genetown
BostonGene Announces Publication in Collaboration with National Cancer Institute and National Institute of Allergy and Infectious Diseases in Cancer Cell
BostonGene Announces Publication in Collaboration with National Cancer Institute and National Institute of Allergy and Infectious Diseases in Cancer Cell.
March 7, 2024
·
4 min read
Business
ATCC Announces Award from National Institute of Allergy and Infectious Diseases to Support Its Preclinical Services for Biopharmaceutical Product Development
ATCC , the world’s premier biological materials management and standards organization, today announced that it has been awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract 75N93023D00009 by the National Institute of Allergy and Infectious Diseases ( NIAID ), part of the National Institutes of Health (NIH).
November 7, 2023
·
2 min read
Policy
U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri’s PLX-R18 Acute Radiation Syndrome Contract
Pluri Inc., a leading biotechnology company that transforms cells into solutions, announced the U.S. National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has exercised its option for year two of the three-year $4.2 million contract it entered into with Pluri in July 2023.
June 6, 2024
·
7 min read
Drug Development
Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to National Institute of Allergy and Infectious Diseases for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
Napo Pharmaceuticals (Napo), a Jaguar Health (NASDAQ:JAGX) (Jaguar) family company, today announced that it has submitted a grant application to the National Institute of Allergy and Infectious Diseases (NIAID) for funding to support Napo’s Phase I study of NP-300.
September 12, 2023
·
5 min read
Business
Logix Biosciences Enters into Agreement with Mayo Clinic to Advance Development of Therapeutics for Allergy Relief, Mutating Infectious Diseases and Antimicrobial Resistance
Logix Biosciences, a biopharmaceutical company focused on the discovery and development of a pipeline of precision therapeutics and companion diagnostics for allergy relief, protection against infectious diseases, and antimicrobial resistance (AMR), today announced it has entered into a know-how agreement with Mayo Clinic.
June 12, 2024
·
2 min read
VyraMed’s Multi-Tissue Platform (MTP) from FetTech Found Highly Effective at Preventing VZV (Shingles) From Spreading in the Skin in NIAID-Sponsored Ex Vivo Human Skin Study
VyraMed and FetTech announced today initial results emerging from their ex vivo human skin study sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
December 7, 2023
·
3 min read
Bio NC
Thermo Fisher Scientific Selected as the Transplantation Statistical and Clinical Coordinating Center (T-SCCC) for the U.S. National Institute of Allergy and Infectious Diseases
Thermo Fisher Scientific Selected as the Transplantation Statistical and Clinical Coordinating Center (T-SCCC) for the U.S. National Institute of Allergy and Infectious Diseases.
August 10, 2023
·
4 min read
Biotech Beach
Trethera Receives Grant from National Institute of Allergy and Infectious Diseases for the Advancement of TRE-515 in Lupus
Trethera Corporation announced that it was awarded a $0.6M Small Business Technology Transfer grant from the National Institute for Allergy and Infectious Diseases.
June 27, 2023
·
6 min read
1 of 71,802
Next
